Gyeongnam Biopharma Submits Audit Report with 'Appropriate' Opinion... "Scheduled for Delisting from Management Stocks"
[Asia Economy Reporter Hyunseok Yoo] Gyeongnam Biopharma announced on the 23rd through a disclosure that it has submitted the 2021 audit report with an 'unqualified' opinion.
Gyeongnam Biopharma was designated as a management item last August due to an evaluation loss on derivative financial liabilities, but through this disclosure, it is expected to be removed from the management item list by submitting an audit report with an 'unqualified' opinion.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
A company official stated, "We thank the shareholders who have trusted and waited for us, and we will accelerate management to enhance shareholder value by escaping the management item risk," adding, "We will recover sales by actively pursuing new businesses as well as our existing mask and condom businesses."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
